Key Highlights of the Canadian Thoracic Society's Position Statement on the Optimization of COPD Management During the Coronavirus Disease 2019 Pandemic

Mohit Bhutani; Paul Hernandez; Jean Bourbeau; Gail Dechman; Erika Penz; Raymond Aceron; Marla Beauchamp; Joshua Wald; Michael Stickland; Sharla Rae Olsen; Donna Goodridge

doi:10.1016/j.chest.2020.05.530

Key Highlights of the Canadian Thoracic Society's Position Statement on the Optimization of COPD Management During the Coronavirus Disease 2019 Pandemic

Mohit Bhutani, Paul Hernandez, Jean Bourbeau, Gail Dechman, Erika Penz, Raymond Aceron, Marla Beauchamp, Joshua Wald, Michael Stickland, Sharla Rae Olsen, Donna Goodridge

Medicine

Research output: Contribution to journal › Editorial › peer-review

12 Citations (Scopus)

Original language	English
Pages (from-to)	869-872
Number of pages	4
Journal	Chest
Volume	158
Issue number	3
DOIs	https://doi.org/10.1016/j.chest.2020.05.530
Publication status	Published - Sept 2020

Bibliographical note

Funding Information:
FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: M. Bhutani reports personal fees and grants outside the submitted work from AstraZeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKine Canada Ltd, Novartis , Sanofi -Genzyme, the Canadian Institute Health Research, CHEST, The Lung Association of Alberta, The University of Alberta Hospital Foundation, and Alberta Innovates Health Solutions. P. H. reports grants from the Canadian Institute Health Research, the Lung Association of Nova Scotia, the Nova Scotia Health Authority Research Fund, Astra Zeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, Cyclomedica, Grifols, Respivant, and Vertex; and personal fees from Actelion, Astra Zeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKine Canada Ltd, Novartis, Sanofi-Aventis, and Trudell, outside the submitted work. J. B. reports grants from the Canadian Respiratory Research Network, the Canadian Institute Health Research, and the Respiratory Health Network of the Fonds de la recherche en santé du Québec; grants and personal fees from Astra Zeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKine Canada Ltd, Grifols, Novartis, and Trudell; and personal fees from the Canadian Thoracic Society and CHEST, outside the submitted work. E. P. reports personal fees from Boehringer Ingelheim Canada Ltd, Astra Zeneca Canada Ltd, GlaxoSmithKine Canada Ltd, and Novartis; and grants from the Canadian Institute Health Research, the Saskatchewan Research Foundation, the Respiratory Research Centre, and Astra Zeneca Canada Ltd, outside the submitted work. J. W. reports personal fees from GlaxoSmithKine Canada Ltd and a grant from Fisher & Paykel, outside the submitted work. M. S. reports investigator-initiated funding from the Canadian Institute Health Research, the Natural Sciences and Engineering Research Council of Canada , the Canadian Respiratory Research Network, the Canadian Foundation of Innovation, Alberta Innovates Health Solutions, the Lung Association of Alberta, and the University of Alberta Hospital Foundation/Alberta Boehringer Ingelheim Collaboration. D. G. reports grants from the Canadian Institute Health Research, the Centre for Aging and Brain Health Innovation, the Saskatchewan Health Research Foundation, the Royal University Hospital Foundation, the Lung Association of Saskatchewan, the Canadian Network for the Prevention of Elder Abuse, the Respiratory Research Centre, and the College of Medicine, University of Saskatchewan , outside the submitted work. None declared (G. D., R. A., M. Beauchamp, S.-R., O.).

ASJC Scopus Subject Areas

Pulmonary and Respiratory Medicine
Critical Care and Intensive Care Medicine
Cardiology and Cardiovascular Medicine

Access to Document

10.1016/j.chest.2020.05.530

Cite this

Bhutani, M., Hernandez, P., Bourbeau, J., Dechman, G., Penz, E., Aceron, R., Beauchamp, M., Wald, J., Stickland, M., Olsen, S. R., & Goodridge, D. (2020). Key Highlights of the Canadian Thoracic Society's Position Statement on the Optimization of COPD Management During the Coronavirus Disease 2019 Pandemic. Chest, 158(3), 869-872. https://doi.org/10.1016/j.chest.2020.05.530

Bhutani, M, Hernandez, P, Bourbeau, J, Dechman, G, Penz, E, Aceron, R, Beauchamp, M, Wald, J, Stickland, M, Olsen, SR & Goodridge, D 2020, 'Key Highlights of the Canadian Thoracic Society's Position Statement on the Optimization of COPD Management During the Coronavirus Disease 2019 Pandemic', Chest, vol. 158, no. 3, pp. 869-872. https://doi.org/10.1016/j.chest.2020.05.530

@article{8c589da545bf4d3f8531bc2196e2ebc1,

title = "Key Highlights of the Canadian Thoracic Society's Position Statement on the Optimization of COPD Management During the Coronavirus Disease 2019 Pandemic",

author = "Mohit Bhutani and Paul Hernandez and Jean Bourbeau and Gail Dechman and Erika Penz and Raymond Aceron and Marla Beauchamp and Joshua Wald and Michael Stickland and Olsen, {Sharla Rae} and Donna Goodridge",

note = "Funding Information: FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: M. Bhutani reports personal fees and grants outside the submitted work from AstraZeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKine Canada Ltd, Novartis , Sanofi -Genzyme, the Canadian Institute Health Research, CHEST, The Lung Association of Alberta, The University of Alberta Hospital Foundation, and Alberta Innovates Health Solutions. P. H. reports grants from the Canadian Institute Health Research, the Lung Association of Nova Scotia, the Nova Scotia Health Authority Research Fund, Astra Zeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, Cyclomedica, Grifols, Respivant, and Vertex; and personal fees from Actelion, Astra Zeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKine Canada Ltd, Novartis, Sanofi-Aventis, and Trudell, outside the submitted work. J. B. reports grants from the Canadian Respiratory Research Network, the Canadian Institute Health Research, and the Respiratory Health Network of the Fonds de la recherche en sant{\'e} du Qu{\'e}bec; grants and personal fees from Astra Zeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKine Canada Ltd, Grifols, Novartis, and Trudell; and personal fees from the Canadian Thoracic Society and CHEST, outside the submitted work. E. P. reports personal fees from Boehringer Ingelheim Canada Ltd, Astra Zeneca Canada Ltd, GlaxoSmithKine Canada Ltd, and Novartis; and grants from the Canadian Institute Health Research, the Saskatchewan Research Foundation, the Respiratory Research Centre, and Astra Zeneca Canada Ltd, outside the submitted work. J. W. reports personal fees from GlaxoSmithKine Canada Ltd and a grant from Fisher & Paykel, outside the submitted work. M. S. reports investigator-initiated funding from the Canadian Institute Health Research, the Natural Sciences and Engineering Research Council of Canada , the Canadian Respiratory Research Network, the Canadian Foundation of Innovation, Alberta Innovates Health Solutions, the Lung Association of Alberta, and the University of Alberta Hospital Foundation/Alberta Boehringer Ingelheim Collaboration. D. G. reports grants from the Canadian Institute Health Research, the Centre for Aging and Brain Health Innovation, the Saskatchewan Health Research Foundation, the Royal University Hospital Foundation, the Lung Association of Saskatchewan, the Canadian Network for the Prevention of Elder Abuse, the Respiratory Research Centre, and the College of Medicine, University of Saskatchewan , outside the submitted work. None declared (G. D., R. A., M. Beauchamp, S.-R., O.). ",

year = "2020",

month = sep,

doi = "10.1016/j.chest.2020.05.530",

language = "English",

volume = "158",

pages = "869--872",

journal = "Chest",

issn = "0012-3692",

publisher = "American College of Chest Physicians",

number = "3",

}

TY - JOUR

T1 - Key Highlights of the Canadian Thoracic Society's Position Statement on the Optimization of COPD Management During the Coronavirus Disease 2019 Pandemic

AU - Bhutani, Mohit

AU - Hernandez, Paul

AU - Bourbeau, Jean

AU - Dechman, Gail

AU - Penz, Erika

AU - Aceron, Raymond

AU - Beauchamp, Marla

AU - Wald, Joshua

AU - Stickland, Michael

AU - Olsen, Sharla Rae

AU - Goodridge, Donna

N1 - Funding Information: FINANCIAL/NONFINANCIAL DISCLOSURES: The authors have reported to CHEST the following: M. Bhutani reports personal fees and grants outside the submitted work from AstraZeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKine Canada Ltd, Novartis , Sanofi -Genzyme, the Canadian Institute Health Research, CHEST, The Lung Association of Alberta, The University of Alberta Hospital Foundation, and Alberta Innovates Health Solutions. P. H. reports grants from the Canadian Institute Health Research, the Lung Association of Nova Scotia, the Nova Scotia Health Authority Research Fund, Astra Zeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, Cyclomedica, Grifols, Respivant, and Vertex; and personal fees from Actelion, Astra Zeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKine Canada Ltd, Novartis, Sanofi-Aventis, and Trudell, outside the submitted work. J. B. reports grants from the Canadian Respiratory Research Network, the Canadian Institute Health Research, and the Respiratory Health Network of the Fonds de la recherche en santé du Québec; grants and personal fees from Astra Zeneca Canada Ltd, Boehringer Ingelheim Canada Ltd, GlaxoSmithKine Canada Ltd, Grifols, Novartis, and Trudell; and personal fees from the Canadian Thoracic Society and CHEST, outside the submitted work. E. P. reports personal fees from Boehringer Ingelheim Canada Ltd, Astra Zeneca Canada Ltd, GlaxoSmithKine Canada Ltd, and Novartis; and grants from the Canadian Institute Health Research, the Saskatchewan Research Foundation, the Respiratory Research Centre, and Astra Zeneca Canada Ltd, outside the submitted work. J. W. reports personal fees from GlaxoSmithKine Canada Ltd and a grant from Fisher & Paykel, outside the submitted work. M. S. reports investigator-initiated funding from the Canadian Institute Health Research, the Natural Sciences and Engineering Research Council of Canada , the Canadian Respiratory Research Network, the Canadian Foundation of Innovation, Alberta Innovates Health Solutions, the Lung Association of Alberta, and the University of Alberta Hospital Foundation/Alberta Boehringer Ingelheim Collaboration. D. G. reports grants from the Canadian Institute Health Research, the Centre for Aging and Brain Health Innovation, the Saskatchewan Health Research Foundation, the Royal University Hospital Foundation, the Lung Association of Saskatchewan, the Canadian Network for the Prevention of Elder Abuse, the Respiratory Research Centre, and the College of Medicine, University of Saskatchewan , outside the submitted work. None declared (G. D., R. A., M. Beauchamp, S.-R., O.).

PY - 2020/9

Y1 - 2020/9

UR - http://www.scopus.com/inward/record.url?scp=85089598210&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089598210&partnerID=8YFLogxK

U2 - 10.1016/j.chest.2020.05.530

DO - 10.1016/j.chest.2020.05.530

M3 - Editorial

C2 - 32422130

AN - SCOPUS:85089598210

SN - 0012-3692

VL - 158

SP - 869

EP - 872

JO - Chest

JF - Chest

IS - 3

ER -

Key Highlights of the Canadian Thoracic Society's Position Statement on the Optimization of COPD Management During the Coronavirus Disease 2019 Pandemic

Bibliographical note

ASJC Scopus Subject Areas

Access to Document

Other files and links

Cite this